First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
Rhea-AI Summary
CollPlant (NASDAQ: CLGN) said Mayo Clinic researchers developed a first‑in‑kind fully humanized 3D bioprinted human skin model using CollPlant's plant‑derived recombinant human collagen (rhCollagen) bioink, announced Oct. 16, 2025.
The model combines rhCollagen bioinks with human fibroblasts, melanocytes and keratinocytes and is integrated into a skin‑on‑a‑chip system to evaluate topical and transdermal drug delivery as a non‑animal preclinical platform. Claimed advantages include high‑throughput production, personalized human skin models at scale, reduced animal testing, and potential use in cosmetic and pharmaceutical testing, disease modeling, drug development and regenerative medicine.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CLGN declined 2.71%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $920K from the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
- The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research.
- According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived recombinant human collagen (rhCollagen) with distinct and essential human skin cell types.
- This innovative platform offers a sustainable and ethical solution for cosmetic and pharmaceutical testing, disease modeling, and drug development.
REHOVOT,
The novel model specifically consists of CollPlant's rhCollagen-based bioinks used for 3D bioprinting and human skin fibroblasts, melanocytes and keratinocytes. The integration of these constructs into a skin-on-a-chip system enables the evaluation of topical and transdermal drug delivery in a non-animal model. In addition, the 3D bioprinting of skin using plant-derived rhCollagen presents significant advantages, including high-throughput production of personalized human skin models, and potential applications in regenerative medicine and other areas of medicine.
Yehiel Tal, Chief Executive Officer of CollPlant, commented, "We are excited about the impressive and innovative work resulting from Mayo Clinic's research and utilizing our rhCollagen technology. The model presents significant advantages, including providing a template for producing personalized human skin models at scale, enabling the reduction of animal testing, and creating learnings to apply to advancements in regenerative medicine. The results of this study further substantiate the vast potential of rhCollagen-based bioinks for use in 3D bioprinting applications including in vitro 3D models as well as in regenerative medicine."
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
+ 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2797946/Mayo_Clinic_CollPlant.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/first-in-kind-fully-humanized-3d-bioprinted-human-skin-model-developed-by-mayo-clinic-researchers-using-collplants-rhcollagen-based-bioink-302585959.html
SOURCE CollPlant
FAQ
What did CollPlant and Mayo Clinic announce on October 16, 2025 regarding CLGN?
How does the new 3D bioprinted skin model using CLGN's rhCollagen reduce animal testing?
What cell types are included in the CollPlant‑enabled 3D skin model mentioned by CLGN?
What applications does the Mayo Clinic 3D skin model using CLGN's rhCollagen target?
Does the CollPlant rhCollagen 3D skin model enable personalized testing for CLGN partners?
Will the CLGN‑based skin model be used for topical and transdermal drug delivery testing?
